Ascena spikes with strong quarter

optionMONSTER

Earnings, Sales Better Than Expected

Ascena Retail's profit fell, but not as much as analysts had feared! The company earned $0.26 in its second quarter, while consensus was looking for $0.23. Sales of $1.24 billion also edged ahead of the $1.23 billion average forecast. ASNA climbs 13 percent before the bell on my tradeMONSTER platform.

Strong Clinical Data Lifts AcelRX

AcelRX Pharmaceuticals said that its investigational sublingual Sufentanil NanoTab PCA system met its primary endpoint in the first of two key phase 3 studies. That sends up by ACRX 12 percent in early trading.

More Problems for Impax Labs

Impax Laboratories announced that the U.S. Food & Drug Administration found new problems at its California manufacturing. It's the latest in an ongoing saga with the facility. IPXL is down 20 percent in the premarket.

More From optionMONSTER

View Comments (0)